Alemtuzumab for patients with chronic lymphocytic leukaemia

Abstract

Analysis 1.1. Comparison 1 Anti-leukaemic therapy plus alemtuzumab versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups; unconfounded), Outcome 1 PFS-overall analysis.. .. .. .. .. Analysis 1.2. Comparison 1 Anti-leukaemic therapy plus alemtuzumab versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups; unconfounded), Outcome 2 PFS-subgrouped by treatment regimens.. . Analysis 1.3. Comparison 1 Anti-leukaemic therapy plus alemtuzumab versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups; unconfounded), Outcome 3 PFS-subgrouped by starting point of alemtuzumab. Analysis 1.4. Comparison 1 Anti-leukaemic therapy plus alemtuzumab versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups; unconfounded), Outcome 4 Treatment related mortality.. .. .. .. Analysis 1.5. Comparison 1 Anti-leukaemic therapy plus alemtuzumab versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups; unconfounded), Outcome 5 ORR-overall analysis.. .. .. .. .. Analysis 1.6. Comparison 1 Anti-leukaemic therapy plus alemtuzumab versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups; unconfounded), Outcome 6 ORR-subgrouped by treatment regimens.. . Analysis 1.7. Comparison 1 Anti-leukaemic therapy plus alemtuzumab versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups; unconfounded), Outcome 7 ORR-subgrouped by starting point of alemtuzumab. Analysis 1.8. Comparison 1 Anti-leukaemic therapy plus alemtuzumab versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups; unconfounded), Outcome 8 CRR-overall analysis.. .. .. .. .. Analysis 1.9. Comparison 1 Anti-leukaemic therapy plus alemtuzumab versus anti-leukaemic therapy alone (anti-leukaemic therapy identical in both groups; unconfounded), Outcome 9 CRR-subgrouped by treatment regimens.. . Analysis 1.10. Comparison 1 Anti-leukaemic therapy plus alemtuzumab versus anti-leukaemic therapy alone (antileukaemic therapy identical in both groups; unconfounded

Cytomegalovirus DNAemia and disease: current‐era epidemiology, clinical characteristics and outcomes in cancer patients other than allogeneic haemopoietic transplantation

“…Consistent with previous reports, [6][7][8][9][10] we observed more CMV DNAemia in patients receiving alemtuzumab and idelalisib therapies. In fact, recognition of CMV infection following alemtuzumab and idelalisib has led to clinical guidelines for prospective monitoring of CMV DNA during treatment.…”

“…In fact, recognition of CMV infection following alemtuzumab and idelalisib has led to clinical guidelines for prospective monitoring of CMV DNA during treatment. 6,8,[10][11][12][13] Apart from these therapies with known CMV risk, the magnitude of risk for CMV infection among other novel therapies is still largely undetermined and thus needs to be further evaluated.…”

Cytomegalovirus DNAemia and disease: current‐era epidemiology, clinical characteristics and outcomes in cancer patients other than allogeneic haemopoietic transplantation

“…Consistent with previous reports, [6][7][8][9][10] we observed more CMV DNAemia in patients receiving alemtuzumab and idelalisib therapies. In fact, recognition of CMV infection following alemtuzumab and idelalisib has led to clinical guidelines for prospective monitoring of CMV DNA during treatment.…”

“…In fact, recognition of CMV infection following alemtuzumab and idelalisib has led to clinical guidelines for prospective monitoring of CMV DNA during treatment. 6,8,[10][11][12][13] Apart from these therapies with known CMV risk, the magnitude of risk for CMV infection among other novel therapies is still largely undetermined and thus needs to be further evaluated.…”

Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma

“…42,43 Therefore, we looked at previous therapy in relation to time of first measurable pEBVd to estimate if detection of pEBVd might be treatment-related. Supplemental Table 3 (in the online version) shows systemic therapies received in the pEBVd + cohort before the first measurable pEBVd compared with the EBV − cohort.…”

CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma

“…Since ibrutinib induces lymphocytosis, residual MCL cells in the blood could be cleared by alemtuzumab, as the anti-CD52 antibody is more active in blood than in lymph nodes and could help to yield MRD negativity [55]. However, the observed fast depletion of healthy lymphocytes is consistent with the known serious sideeffect profile of the antibody, including the risk of immunosuppression and viral and opportunistic infections, which must be taken into account in clinical use and may limit its applicability to heavily pretreated MCL patients with poor prognosis [56].…”

Cytomegalovirus DNAemia and disease: current‐era epidemiology, clinical characteristics and outcomes in cancer patients other than allogeneic haemopoietic transplantation

“…Consistent with previous reports, [6][7][8][9][10] we observed more CMV DNAemia in patients receiving alemtuzumab and idelalisib therapies. In fact, recognition of CMV infection following alemtuzumab and idelalisib has led to clinical guidelines for prospective monitoring of CMV DNA during treatment.…”

“…In fact, recognition of CMV infection following alemtuzumab and idelalisib has led to clinical guidelines for prospective monitoring of CMV DNA during treatment. 6,8,[10][11][12][13] Apart from these therapies with known CMV risk, the magnitude of risk for CMV infection among other novel therapies is still largely undetermined and thus needs to be further evaluated.…”

Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma

“…42,43 Therefore, we looked at previous therapy in relation to time of first measurable pEBVd to estimate if detection of pEBVd might be treatment-related. Supplemental Table 3 (in the online version) shows systemic therapies received in the pEBVd + cohort before the first measurable pEBVd compared with the EBV − cohort.…”

CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma

“…Since ibrutinib induces lymphocytosis, residual MCL cells in the blood could be cleared by alemtuzumab, as the anti-CD52 antibody is more active in blood than in lymph nodes and could help to yield MRD negativity [55]. However, the observed fast depletion of healthy lymphocytes is consistent with the known serious sideeffect profile of the antibody, including the risk of immunosuppression and viral and opportunistic infections, which must be taken into account in clinical use and may limit its applicability to heavily pretreated MCL patients with poor prognosis [56].…”

Cytomegalovirus DNAemia and disease: current‐era epidemiology, clinical characteristics and outcomes in cancer patients other than allogeneic haemopoietic transplantation

“…Consistent with previous reports, [6][7][8][9][10] we observed more CMV DNAemia in patients receiving alemtuzumab and idelalisib therapies. In fact, recognition of CMV infection following alemtuzumab and idelalisib has led to clinical guidelines for prospective monitoring of CMV DNA during treatment.…”

“…In fact, recognition of CMV infection following alemtuzumab and idelalisib has led to clinical guidelines for prospective monitoring of CMV DNA during treatment. 6,8,[10][11][12][13] Apart from these therapies with known CMV risk, the magnitude of risk for CMV infection among other novel therapies is still largely undetermined and thus needs to be further evaluated.…”

Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma

“…42,43 Therefore, we looked at previous therapy in relation to time of first measurable pEBVd to estimate if detection of pEBVd might be treatment-related. Supplemental Table 3 (in the online version) shows systemic therapies received in the pEBVd + cohort before the first measurable pEBVd compared with the EBV − cohort.…”

CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma

“…Since ibrutinib induces lymphocytosis, residual MCL cells in the blood could be cleared by alemtuzumab, as the anti-CD52 antibody is more active in blood than in lymph nodes and could help to yield MRD negativity [55]. However, the observed fast depletion of healthy lymphocytes is consistent with the known serious sideeffect profile of the antibody, including the risk of immunosuppression and viral and opportunistic infections, which must be taken into account in clinical use and may limit its applicability to heavily pretreated MCL patients with poor prognosis [56].…”